A Post-transcriptional Compensatory Pathway in Heterozygous Ventricular Myosin Light Chain 2-Deficient Mice Results in Lack of Gene Dosage Effect during Normal Cardiac Growth or Hypertrophy*

Susumu Minamisawa, Yusu Gu, John Ross Jr., Kenneth R. Chien, and Ju ChenDagger

From the Department of Medicine and the Center for Molecular Genetics, University of California at San Diego, School of Medicine, La Jolla, California 92093-0613

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Our previous study of homozygous mutants of the ventricular specific isoform of myosin light chain 2 (mlc-2v) demonstrated that mlc-2v plays an essential role in murine heart development (Chen, J., Kubalak, S. W., Minamisawa, S., Price, R. L., Becker, K. D., Hickey, R., Ross, J., Jr., and Chien, K. R. (1998) J. Biol. Chem. 273, 1252-1256). As gene dosage of some myofibrillar proteins can affect muscle function, we have analyzed heterozygous mutants in depth. Ventricles of heterozygous mutants displayed a 50% reduction in mlc-2v mRNA, yet expressed normal levels of protein both under basal conditions and following induction of cardiac hypertrophy by aortic constriction. Heterozygous mutants exhibited cardiac function comparable to that of wild-type littermate controls both prior to and following aortic constriction. There were no significant differences in contractility and responses to calcium between wild-type and heterozygous unloaded cardiomyocytes. We conclude that heterozygous mutants show neither a molecular nor a physiological cardiac phenotype either at base line or following hypertrophic stimuli. These results suggest that post-transcriptional compensatory mechanisms play a major role in maintaining the level of MLC-2v protein in murine hearts. In addition, as our mlc-2v knockout mutants were created by a knock-in of Cre recombinase into the endogenous mlc-2v locus, this study demonstrates that heterozygous mlc-2v cre knock-in mice are appropriate for ventricular specific gene targeting.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Sarcomeres, the functional units of striated muscle, are composed of >20 known proteins, precisely organized in a nearly crystalline fashion. Mechanisms by which these proteins are assembled remain largely unknown. The genetic approach of inactivating genes encoding specific sarcomeric proteins has been used to understand the role of stoichiometry in sarcomeric assembly. One important issue is the gene dosage effect of these proteins on muscle organization and function. Drosophila heterozygous mutants with one functional copy of either actin or myosin heavy chain (MHC)1 gene have dysfunctional flight muscle, cannot fly, and have abnormal sarcomeric structure (1). Heterozygous mutants display a 50% reduction in either actin or MHC protein, respectively. Interestingly, the sarcomeric structure of muscle from double heterozygous mutants with single copies of both actin and MHC genes is less abnormal than muscle from either of the single heterozygous mutants. Consequently, double heterozygotes are capable of weak flight (1). These data indicate that variations in sarcomeric protein stoichiometry can affect myofibrillar organization and function. Recently, similar studies have been performed in mouse knockout models. Heterozygous alpha -MHC knockout mice have ~50 and 25% reductions in alpha -MHC mRNA and protein, respectively, compared with wild-type littermates. Heterozygous mice have impaired cardiac function and abnormal sarcomeric organization (2). On the other hand, heterozygous alpha -tropomyosin knockout mice display a 50% reduction in mRNA but similar levels of alpha -tropomyosin protein compared with wild-type littermates and have no detectable cardiac abnormalities (3, 4). However, to date, no studies have been performed with these mutant mice to examine the consequences of the heterozygous state on cardiac function under conditions that induce hypertrophy.

Myosin light chain 2 (MLC-2), the regulatory myosin light chain, plays an essential role in vertebrate smooth muscle contraction (5-7). In vertebrate striated muscle, MLC-2 is thought to have only a modulatory effect on contraction (8-11). However, a recent gene targeting study has revealed a selective requirement for the ventricular specific isoform of mlc-2 (mlc-2v) in embryonic murine heart function (12). Homozygous mlc-2v mutant embryos die at approximately embryonic day 12.5. The null mutants have a significantly reduced left ventricular ejection fraction. Ultrastructural analysis revealed defects in sarcomeric assembly. These data indicate that mlc-2v plays an important role in cardiac function and myofibrillogenesis during mammalian heart development. Moreover, it has been shown that missense mutations in the human MLC-2v gene result in a rare form of hypertrophic cardiomyopathy (13). However, there are no data to distinguish whether the disease results simply from "loss" of function (gene dosage) or an alternative mechanism.

Drosophila has a single mlc-2 gene, and homozygous mlc-2 mutants are embryonic lethal. Heterozygous mutants can survive, but cannot fly due to dysfunctional flight muscles that display abnormal sarcomeric structure (14). These heterozygous mutants display a 50% reduction in mlc-2 mRNA with a 25% reduction in MLC-2 protein compared with wild-type lit4termates. To determine whether mlc-2v exhibits a similar gene dosage effect in mammalian hearts, we have performed in-depth analyses of heterozygous mlc-2v mutant mice.

Furthermore, we created the original mlc-2v knockout mice (12) by a knock-in of Cre recombinase into the endogenous mlc-2v locus to achieve two goals: 1) to understand the physiological importance of mlc-2v in mammalian hearts and 2) to use the heterozygous mlc-2v cre knock-in mice for ventricular cardiomyocyte-specific gene targeting, as described by Chen et al. (15). In this report, we demonstrate that heterozygous mlc-2v cre knock-in mice are indistinguishable from wild-type mice in all aspects and display normal levels of MLC-2v protein despite a 50% reduction in mRNA. Thus, we have validated the potential utility of the mlc-2v cre knock-in system as a valuable approach for ventricular restricted gene targeting.

    MATERIALS AND METHODS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Generation of mlc-2v Knockout/cre Knock-in Mice-- The mlc-2v targeting construct has been described elsewhere (12). By homologous recombination, Cre recombinase cDNA was placed into the endogenous mlc-2v locus. This study used the heterozygous mlc-2v mutants, which have one copy of Cre recombinase cDNA in the mlc-2v locus.

Echocardiographic Analysis-- Mice were anesthetized with 20 ml of 2.5% Avertin/kg of body weight given intraperitoneally, and transthoracic echocardiography was performed before and 7 days after transverse aortic constriction (TAC) as described in detail elsewhere (16).

Induction of Pressure Overload Cardiac Hypertrophy-- Pressure overload was produced in mice at 8 weeks of age by TAC as described previously (17). At 7 days following surgery, the gradient of the arterial blood pressure between the constriction was measured. Six heterozygous mlc-2v mutants and six wild-type mice showing an adequate pressure gradient (>25 mm Hg) were subjected to further studies.

Northern Blot Analysis-- Ten micrograms of total RNA from adult left ventricles was used for Northern blot analyses. To characterize the expression of mlc-2v and the atrial isoform of MLC-2 (mlc-2a), the same probes described previously (18) were used. Expression of atrial natriuretic factor and skeletal alpha -actin mRNAs was examined as a molecular marker for hypertrophy.

Western Blot Analysis-- Five micrograms of myofibrillar protein extracts from left ventricles (19) was electrophoresed on 12.5% SDS-polyacrylamide gels and either stained with Coomassie Blue or subjected to Western blotting analysis. Anti-MLC-2v and anti-MLC-2a polyclonal antibodies have been described previously (18).

Myocyte Shortening Measurement (Edge Detection)-- Ventricular myocytes were prepared from the left ventricles of heterozygous mlc-2v and wild-type littermates at 10 weeks of age. The mouse heart was excised, and the aorta was cannulated and mounted onto a Langendorff perfusion apparatus. The heart was perfused for 4 min in modified Joklik's minimal essential medium (Life Technologies, Inc.) consisting of 113 mM NaCl, 4.7 mM KCl, 0.6 mM KH2PO4, 0.6 mM Na2HPO4, 1.2 mM MgSO4, 12 mM NaHCO3, 20 mM D-glucose, 10 mM HEPES, 30 mM taurine, 2 mM creatine, and 2 mM carnitine (pH 7.4). Perfusion was then switched to a modified Joklik's minimal essential medium plus 0.1% (w/v) collagenase type II (Worthington). After 15 min of enzymatic digestion, the atria and right ventricle were removed; the left ventricle was cut into several pieces; and the cells were dispersed by gentle agitation. Myocytes were filtered and washed, and 1 mM calcium was reintroduced gradually to the cells.

Isolated cardiomyocytes were transferred to a temperature-controlled perfusion chamber (HCB-101, Crescent Electronics) located on the stage of an inverted microscope (Nikon Diaphot-TMD). Cell shortening was measured using a video edge motion detector (Crescent Electronics) interfaced to a standard CCD camera (Philips Technologies), which was attached to the microscope. A 40× Nikon phase II objective was used. Cells were stimulated at 0.5 Hz with a 5-ms pulse duration by a BMS 414 electrostimulator (Crescent Electronics). Edge detection measurements were performed on cardiomyocytes at 22 °C in continuously circulating Tyrode's solution on cells. The concentration of calcium in Tyrode's solution was subsequently changed from 1 to 2 to 4 mM.

Myosin ATPase Assay-- Fresh myosin preparations were obtained from each group of left ventricles by the method described previously (20). Ca2+-ATPase, K+-EDTA-ATPase, and actin-activated ATPase activities in myosin preparations were determined using the method of Ikebe and Hartshorne (21) with some modification. Ca2+-ATPase activity was measured at 23 °C in 0.1 mg/ml myosin, 1 mM ATP, 10 mM CaCl2, 50 mM Tris-HCl (pH 7.5), and 50 mM KCl. K+-EDTA-ATPase activity was measured at 23 °C in 0.1 mg/ml myosin, 1 mM ATP, 10 mM EDTA, 50 mM Tris-HCl (pH 7.5), and 0.6 M KCl. Actin-activated ATPase activity was measured at 23 °C in 0.1 mg/ml myosin, 1 mM ATP, 6 mM MgCl2, 0.5 mM EGTA, 20 mM imidazole HCl (pH 7.5), and 50 mM KCl with or without 1 mg/ml F-actin.

Statistical Analysis-- Data are indicated as means ± S.E. Statistical comparisons between the wild-type mice and mlc-2v mutants were done by unpaired Student t test. Echocardiographic data before and after transverse aortic constriction were compared by paired t test. A p value of <0.05 was considered significant.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

Characterization of Heterozygous mlc-2v Mutant Mice-- Our previous study demonstrated that homozygous mlc-2v-/- offspring die at ~12.5 days post coitum due to cardiac dysfunction, indicating that mlc-2v is an essential component of the myocardial contractile apparatus (12). Heterozygous mlc-2v mutants can survive a full life span and reproduce normally. We performed an in-depth analysis of heterozygous mlc-2v mutants. There were no significant differences in heart/body weight ratios between wild-type mice (4.24 ± 0.34, n = 13) and mlc-2v mutants (4.20 ± 0.33, n = 13). Histologically, heterozygous mlc-2v mutants displayed normal sarcomeric assembly in the ventricular wall (data not shown), although our previous study demonstrated that homozygous mlc-2v mutants exhibit a disrupted myofibrillar organization during cardiogenesis (12).

Post-transcriptional Regulation of MLC-2v Expression-- Quantitative Northern blot analysis indicated that the level of mlc-2v transcripts in ventricles of adult heterozygous mlc-2v mutant mice decreased ~50% compared with wild-type littermates (Fig. 1A). However, the amount of MLC-2v protein in ventricular myofibrillar preparations of both wild-type mice and heterozygous mlc-2v mutants was indistinguishable when corrected for the amount of protein loaded by using amounts of tropomyosin as a standard (Fig. 1B).


View larger version (64K):
[in this window]
[in a new window]
 
Fig. 1.   RNA and protein analyses in heterozygous mlc-2v mutants and wild-type littermates. A, Northern blot analysis of adult (2-month-old) ventricular RNA. Ten micrograms of total RNA was used for each sample. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. B, myofilamentous proteins from adult (2-month-old) ventricles were analyzed by SDS/glycerol-polyacrylamide gel electrophoresis and stained with Coomassie Blue. Five micrograms of protein was loaded in each lane. TM, tropomyosin; TNI, troponin I.

To examine whether the regulation of mRNA and protein expression would be modified by cardiac hypertrophic stimuli, we compared the levels of mlc-2v mRNA and protein following induction of hypertrophy by TAC. Both prior to and following TAC, heterozygous mlc-2v mutants exhibited normal levels of MLC-2v protein (Fig. 2) and a 50% reduction in mRNA (Fig. 3) relative to wild-type littermates as revealed by SDS-polyacrylamide gel electrophoresis and Northern blot analyses.


View larger version (71K):
[in this window]
[in a new window]
 
Fig. 2.   Protein analysis before and after TAC. Myofilamentous proteins from ventricles before and after TAC were analyzed by SDS/glycerol-polyacrylamide gel electrophoresis and stained with Coomassie Blue. Five micrograms of protein was loaded in each lane. Sham, sham operation; TM, tropomyosin; TNI, troponin I.


View larger version (38K):
[in this window]
[in a new window]
 
Fig. 3.   RNA analysis before and after TAC. Ventricular mRNA was analyzed by Northern blotting before and after TAC. Ten micrograms of total RNA was used for each sample. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used as an internal control. Sham, sham operation; ANF, atrial natriuretic factor.

In addition to MLC-2v, MLC-2a is abundantly expressed in the ventricular chamber at the earliest stages of murine cardiogenesis (18). Our previous studies showed that MLC-2a protein content in the ventricular chamber is dramatically increased in mlc-2v null mutant embryos at 12 days post coitum, although there are no significant differences in the mlc-2a mRNA levels between wild-type and homozygous mlc-2v mutant embryos (12). Therefore, we examined the expression of MLC-2a protein in ventricles from adult heterozygous mlc-2v mutants by Western blot analysis. No detectable MLC-2a protein was found in ventricles of wild-type mice or heterozygous mlc-2v mutants before or after TAC (data not shown).

Changes in Molecular Markers of Hypertrophy-- To elucidate whether there are differences in expression of hypertrophic response genes in wild-type mice and heterozygous mlc-2v mutants, we examined the expression of atrial natriuretic factor and skeletal alpha -actin mRNAs following TAC. Hypertrophic stimuli resulted in comparable increases in expression of atrial natriuretic factor and skeletal alpha -actin mRNAs in both groups. Fig. 3 shows a representative Northern blot that examined atrial natriuretic factor expression.

Examination of Global Cardiac Function by Echocardiography-- Cardiac function was evaluated noninvasively by echocardiography prior to and following TAC. Under basal conditions, all echocardiographic parameters were equivalent in both groups (Table I). Similar pressure gradients between the aortic constriction were produced in both groups (Table II). Left ventricular weight/body weight ratios were also similar in both groups following TAC, confirming that the amount of hypertrophic stimulus was comparable for each group. In both groups, left ventricular wall thickness and percent fractional shortening increased in response to TAC. These data indicate that global cardiac function and response to hypertrophic stimuli are unaffected in heterozygous mlc-2v mutants.

                              
View this table:
[in this window]
[in a new window]
 
Table I
Echocardiographic measurements under basal conditions
All data are presented as means ± S.E. BW, body weight; HR, heart rate; LVEDD, end-diastolic left ventricular dimension; LVESD, end-systolic left ventricular dimension; PWth, left ventricular posterior wall thickness; IVSth, interventricular wall thickness; LV%FS, left ventricular percent fractional shortening; Vcf, velocity of circumferential fiber shortening. bpm, beats/min; circ, circumference.

                              
View this table:
[in this window]
[in a new window]
 
Table II
Comparative echocardiographic measurements before and after induction of hypertrophy by TAC
See the legend to Table I for details and definitions of abbreviations. LVW, left ventricular weight; PG, pressure gradient. Data comparison was carried out before and after TAC in either group. bpm, beats/min; circ, circumference.

Mechanical Properties of Ventricular Cardiomyocytes Remain Normal in Heterozygous mlc-2v Mutant Mice-- To characterize contractile properties of cardiac myocytes isolated from wild-type mice or heterozygous mlc-2v mutants, unloaded contractile motion was monitored. Cardiac myocytes isolated from heterozygotes or wild-type littermates were found to be morphologically indistinguishable. Unloaded contractile motion was normalized to resting cell length. Table III shows that percent cell fractional shortening, -dL/dt, and +dL/dt were comparable in wild-type and heterozygous mlc-2v mutant cells at various extracellular calcium concentrations. Additionally, Ca2+-ATPase, K+-EDTA-ATPase, and actin-activated ATPase activities in myosin preparations isolated from wild-type mice and heterozygous mlc-2v mutants displayed no statistical difference (Table IV). These data therefore suggest that mechanical properties of myocytes in heterozygous mlc-2v mutants are indistinguishable from those in wild-type littermates.

                              
View this table:
[in this window]
[in a new window]
 
Table III
Ventricular myocyte mechanical properties with changes of calcium concentration
All data are presented as means ± S.E. Note that measurements were performed on nine ventricular myocytes from three wild-type mice and on ten ventricular myocytes from three heterozygous mice. -dL/dt, the rate of shortening; +dL/dt, the rate of relengthening.

                              
View this table:
[in this window]
[in a new window]
 
Table IV
ATPase activities of heterozygous mlc-2v mutants and wild-type littermates
All data are presented as means ± S.E. Measurements were done on six independent myosin preparations from the left ventricles in each group.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES

There were two main goals for this study: 1) to determine whether mlc-2v exhibits a gene dosage effect in mammalian heart and 2) to evaluate the validity of utilizing mlc-2v cre knock-in mice for ventricular specific gene targeting. Our previous study revealed that mlc-2v null mutants are embryonic lethal at ~12.5 post coitum due to cardiac dysfunction and exhibit abnormal sarcomeric assembly (12), which suggests that mlc-2v plays an essential role in cardiac function and myofibrillogenesis during development. However, this study has shown that, although heterozygous mlc-2v mice display a 50% reduction in mlc-2v mRNA levels, they exhibit no reduction in endogenous MLC-2v protein levels. Heterozygous mice have neither a molecular nor a physiological cardiac phenotype either at base line or following hypertrophic stimuli. These results suggest that, due to post-transcriptional regulation, a single mlc-2v allele is sufficient to produce normal levels of MLC-2v protein and to maintain normal sarcomeric function and development in mouse heart. In addition, our results provide the first evidence that this post-transcriptional regulation can operate following induction of cardiac hypertrophy. In a transgenic approach by other investigators, a 10-fold overexpression of mlc-2v mRNA in murine ventricle failed to increase expression of MLC-2v protein (22). Thus, it appears that mlc-2v is strictly regulated at the post-transcriptional level in murine heart.

A similar post-transcriptional regulatory mechanism has been observed for alpha -tropomyosin, where overexpression of alpha -tropomyosin mRNA or the presence of a single alpha -tropomyosin allele does not affect normal levels of alpha -tropomyosin protein in murine heart (3, 4). These data may suggest that haploinsufficiency is not a causative mechanism for human hypertrophic cardiomyopathies that result from mutations in MLC-2v (13) or in alpha -tropomyosin (23). However, whether similar post-transcriptional regulation of these myofibrillar proteins is operative in human heart is currently unknown. In contrast to these results with MLC-2v and alpha -tropomyosin, heterozygous alpha -MHC knockout mice, in which cardiac function is impaired, display ~50 and 25% reductions in alpha -MHC mRNA and protein, respectively. These results suggest that two MHC alleles are necessary and that post-transcriptional regulation cannot maintain normal protein levels in murine hearts (2). Another compensatory mechanism has been demonstrated in cardiac alpha -actin knockout mice. Cardiac alpha -actin heterozygous mutants exhibit increased expression of various actin isoforms to compensate for reduced cardiac alpha -actin protein expression (24). In heterozygous mlc-2v mutants, this type of compensatory mechanism involving other isoforms does not seem to be activated, as our data showed that there was no detectable MLC-2a protein in adult ventricles of heterozygous mlc-2v mutants. These results indicate that post-transcriptional controls play a major role in determining overall sarcomeric protein stoichiometry under conditions of increased or decreased mRNA levels.

There is only one mlc-2 gene in Drosophila. Interestingly, heterozygous mlc-2 mutants can survive but cannot fly due to dysfunctional flight muscles, which display abnormal sarcomeric structure. Heterozygous mutants display a 50% reduction in mlc-2 mRNA with a 25% reduction in MLC-2 protein (14). Therefore, mlc-2 exhibits a gene dosage effect in Drosophila indirect flight muscle. Similar results have also been shown in Drosophila heterozygous mutants with one functional copy of either actin or MHC gene (1). These data suggest that mechanisms regulating myofibrillar protein expression are specific for each gene locus in a species-dependent manner.

Gene targeting and transgenesis are strong tools for understanding the in vivo function of a gene of interest. However, a disrupted gene sometimes results in embryonic lethality, which makes it difficult to undertake further studies, particularly for genes associated with heart development (15, 25). Moreover, conventional gene targeting may not determine whether a given phenotype is due to gene ablation in a particular cell type, if the targeted gene is expressed in diverse cell types. Conditional knockout and transgenesis strategies can overcome these limitations (26). mlc-2v knockout mutants were created by a knock-in strategy to insert the Cre recombinase coding sequence into the endogenous mlc-2v locus (12). The mlc-2v gene is the earliest marker of ventricular specification during murine cardiogenesis. Thus, the mlc-2v cre knock-in mice can be used for ventricular specific conditional gene targeting. Recently, we achieved ventricular cardiomyocyte-specific gene targeting of the retinoid X receptor alpha  gene by crossing heterozygous mlc-2v cre knock-in mice with mice homozygous for a "floxed" retinoid X receptor alpha  gene (15). Our laboratory and others have been creating other ventricular specific knockout mice by crossing our mlc-2v cre knock-in mice with various mouse lines containing floxed alleles of interest (27). Therefore, it is of utmost importance to fully characterize the heterozygous mlc-2v cre knock-in mice, as all of these conditional knockout mice will be heterozygous at the mlc-2v locus. This study has demonstrated that mlc-2v cre knock-in mice do not exhibit apparent cardiac phenotypes either at base line or following a hypertrophic stimulus. Thus, we conclude that the mlc-2v cre knock-in system is a valid approach for further ventricular specific knockout strategies to explore molecular mechanisms of cardiac hypertrophy and heart development.

    ACKNOWLEDGEMENTS

We are grateful to Dr. Sylvia Evans for critical reading of the manuscript and to Dr. Masataka Sata for sharing knowledge about myosin ATPase assays. We thank Nancy Dalton for expert technical assistance with mouse echocardiography and Julie Sheridan for professional animal care.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grant HL-46345 and the Richard D. Winter Fund.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Medicine, University of California at San Diego, School of Medicine, 9500 Gilman Dr., La Jolla, CA 92093-0613. Tel.: 619-822-2452; Fax: 619-534-8081; E-mail: juchen{at}ucsd.edu.

    ABBREVIATIONS

The abbreviations used are: MHC, myosin heavy chain; MLC-2, myosin light chain 2; MLC-2v, ventricular MLC-2; MLC-2a, atrial MLC-2; TAC, transverse aortic constriction.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
MATERIALS AND METHODS
RESULTS
DISCUSSION
REFERENCES
  1. Beall, C. J., Sepanski, M. A., and Fyrberg, E. A. (1989) Genes Dev. 3, 131-140[Abstract]
  2. Jones, W. K., Grupp, I. L., Doetschman, T., Grupp, G., Osinska, H., Hewett, T. E., Boivin, G., Gulick, J., Ng, W. A., and Robbins, J. (1996) J. Clin. Invest. 98, 1906-1917[Abstract/Free Full Text]
  3. Blanchard, E. M., Iizuka, K., Christe, M., Conner, D. A., Geisterfer, L. A., Schoen, F. J., Maughan, D. W., Seidman, C. E., and Seidman, J. G. (1997) Circ. Res. 81, 1005-1010[Abstract/Free Full Text]
  4. Rethinasamy, P., Muthuchamy, M., Hewett, T., Boivin, G., Wolska, B. M., Evans, C., Solaro, R. J., and Wieczorek, D. F. (1998) Circ. Res. 82, 116-123[Abstract/Free Full Text]
  5. Allen, B. G., and Walsh, M. P. (1994) Trends Biochem. Sci. 19, 362-368[CrossRef][Medline] [Order article via Infotrieve]
  6. Moussavi, R. S., Kelley, C. A., and Adelstein, R. S. (1993) Mol. Cell. Biochem. 128, 219-227
  7. Somlyo, A. P., and Somlyo, A. V. (1994) Nature 372, 231-236[CrossRef][Medline] [Order article via Infotrieve]
  8. Sweeney, H. L., Bowman, B. F., and Stull, J. T. (1993) Am. J. Physiol. 264, C1085-C1095[Abstract/Free Full Text]
  9. Lowey, S., Waller, G. S., and Trybus, K. M. (1993) Nature 365, 454-456[CrossRef][Medline] [Order article via Infotrieve]
  10. Diffee, G. M., Greaser, M. L., Reinach, F. C., and Moss, R. L. (1995) Biophys. J. 68, 1443-1452[Abstract]
  11. Szczesna, D., Zhao, J., and Potter, J. D. (1996) J. Biol. Chem. 271, 5246-5250[Abstract/Free Full Text]
  12. Chen, J., Kubalak, S. W., Minamisawa, S., Price, R. L., Becker, K. D., Hickey, R., Ross, J., Jr., and Chien, K. R. (1998) J. Biol. Chem. 273, 1252-1256[Abstract/Free Full Text]
  13. Poetter, K., Jiang, H., Hassanzadeh, S., Master, S. R., Chang, A., Dalakas, M. C., Rayment, I., Sellers, J. R., Fananapazir, L., and Epstein, N. D. (1996) Nat. Genet. 13, 63-69[Medline] [Order article via Infotrieve]
  14. Warmke, J., Yamakawa, M., Molloy, J., Falkenthal, S., and Maughan, D. (1992) J. Cell Biol. 119, 1523-1539[Abstract]
  15. Chen, J., Kubalak, S., and Chien, K. (1998) Development (Camb.) 125, 1943-1949[Abstract/Free Full Text]
  16. Tanaka, N., Dalton, N., Mao, L., Rockman, H. A., Peterson, K. L., Gottshall, K. R., Hunter, J. J., Chien, K. R., and Ross, J., Jr. (1996) Circulation 94, 1109-1117[Abstract/Free Full Text]
  17. Rockman, H. A., Ross, R. S., Harris, A. N., Knowlton, K. U., Steinhelper, M. E., Field, L. J., Ross, J., Jr., and Chien, K. R. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 8277-8281[Abstract]
  18. Kubalak, S. W., Miller-Hance, W. C., O'Brien, T. X., Dyson, E., and Chien, K. R. (1994) J. Biol. Chem. 269, 16961-16970[Abstract/Free Full Text]
  19. Solaro, R. J., Pang, D. C., and Briggs, F. N. (1971) Biochim. Biophys. Acta. 245, 259-262[Medline] [Order article via Infotrieve]
  20. Sata, M., Sugiura, S., Yamashita, H., Momomura, S., and Serizawa, T. (1996) Circulation 93, 310-317[Abstract/Free Full Text]
  21. Ikebe, M., and Hartshorne, D. J. (1985) Biochemistry 24, 2380-2387[Medline] [Order article via Infotrieve]
  22. Palermo, J., Gulick, J., Colbert, M., Fewell, J., and Robbins, J. (1996) Circ. Res. 78, 504-509[Abstract/Free Full Text]
  23. Thierfelder, L., Watkins, H., MacRae, C., Lamas, R., McKenna, W., Vosberg, H. P., Seidman, J. G., and Seidman, C. E. (1994) Cell 77, 701-712[Medline] [Order article via Infotrieve]
  24. Kumar, A., Crawford, K., Close, L., Madison, M., Lorenz, J., Doetschman, T., Pawlowski, S., Duffy, J., Neumann, J., Robbins, J., Boivin, G. P., O'Toole, B. A., and Lessard, J. L. (1997) Proc. Natl. Acad. Sci. U. S. A. 94, 4406-4411[Abstract/Free Full Text]
  25. Sucov, H. M., Dyson, E., Gumeringer, C. L., Price, J., Chien, K. R., and Evans, R. M. (1994) Genes Dev. 8, 1007-1018[Abstract]
  26. Rajewsky, K., Gu, H., Kuhn, R., Betz, U. A., Muller, W., Roes, J., and Schwenk, F. (1996) J. Clin. Invest. 98, 600-603[Free Full Text]
  27. Hirota, H., Chen, J., Betz, V. A., Rajewsky, K., Gu, Y., Ross, J., Jr., Muller, W., and Chien, K. R. (1999) Cell, in press


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.